Indeed, a high abundance of M2 macrophages [for example, CD204+ TAMs (25)] in the TME is often associated with poor clinical outcomes in patients, while an increase in M1 macrophage (for example, HLA-DR+ TAMs) abundance in tumors often correlates with better prognosis for lung cancer patients (26, 27). This evidence concerns the gene MSR1 and lung cancer.